Abstract Since the Von Hippel–Lindau (VHL) disease tumour suppressor gene VHL was
identified in 1993 as the genetic basis for a rare disorder, it has proved to be of wide medical …

Simple Summary The treatment of renal cancer is currently based on the use of
antiangiogenic drugs targeting the VEGF-A pathway and/or immunotherapy targeting …

Mutations in VHL underlie von Hippel–Lindau (VHL) disease, a hereditary cancer syndrome
with several subtypes depending on the risk of developing certain combination of classic …

Continuous activation of hypoxia-inducible factor (HIF) is important for progression of renal
cell carcinoma (RCC) and acquired resistance to antiangiogenic multikinase and mTOR …

Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …

Emerging evidence suggests that cancer metabolism is closely associated to the serine
biosynthesis pathway (SSP), in which glycolytic intermediate 3-phosphoglycerate is …

Hypoxia-inducible factor-2α (HIF-2α) plays an important role in tumor progression and
metastasis. A number of studies have evaluated the correlation between HIF-2α …

Personalized medicine involves the selection of the safest and most effective
pharmacological treatment based on the molecular characteristics of the patient. In the case …

Abstract The von Hippel-Lindau (VHL) gene is often inactivated in sporadic renal cell
carcinoma (RCC) by mutation or promoter hypermethylation. The prognostic or predictive …

Background Vascular endothelial growth factor (VEGF)-targeted therapy is the currently
standard treatment for advanced and metastatic renal cell carcinoma (RCC). Multiple …